Rhythm Pharmaceuticals, Inc.

RYTM Healthcare Biotechnology

Rhythm Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $189.8 million, up 45.8% from fiscal 2024.

Revenue
+79.6%
EPS
+26.9%
Free cash flow
+95.4%

Quarter to September 2026, against a year earlier

112.38 7.36 +7.01%
Market cap
$7.3B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
6/9
Altman Z
15.89
Beneish M
−2.93
Dividend safety
n/a

Rhythm Pharmaceuticals, Inc. (RYTM) Operating margin

Alert me on Operating margin

Rhythm Pharmaceuticals, Inc.'s operating margin over the twelve months to 30 September 2026 was −66.7%, up 34.5 percentage points from fiscal 2025 (−101.2%). Over the past ten years it has ranged from −5,391.9% (fiscal 2021) to 0.00% (fiscal 2020); the current reading is higher than 45% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Operating margin, annual

Embed this chart

Annual newest first

Period Operating margin Change (points)
FY2025 −101.2% 102.85
FY2024 −204.0% 34.06
FY2023 −238.1% 519.82
FY2022 −757.9% 4,633.93
FY2021 −5,391.9% (5,391.85)
FY2020 0.00% 0.00
FY2019 0.00% 0.00
FY2018 0.00% 0.00
FY2017 0.00% 0.00
FY2016 0.00% 0.00

Quarterly newest first

Period Operating margin Change (points)
Sep 2026 −42.6% 25.51
Jun 2026 −68.1% 18.97
Mar 2026 −87.1% (4.91)
Dec 2025 −82.2% 20.44
36 more quarters

Against its own ten years

Low −5,391.9% High 0.00%
Ten-year median 0.00%
Current reading's percentile 100

Operating margin against peers

What Operating margin is

EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.

EBIT ÷ Revenue

The full definition of Operating margin →

More on RYTM